MYC, SLC1A5, mTORC1, and glutaminase could be further utilized as a biomarker to recognize glutamine-addicted cancers (Yuneva et al., 2007; Wise and Thompson, 2010; Bhutia and Ganapathy, 2016). This evidence concerns the gene GLS and cancer.